← All trials
NCT04150835
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2019
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peking UniversityLead sponsor
- Anhui Medical UniversityCollaborator
- Peking UniversityOverall official - principal investigator
- China Medical UniversityCollaborator
- Guangxi Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Henan Medical UniversityCollaborator
- Jilin UniversityCollaborator
- Shaanxi University of Chinese MedicineCollaborator
- Shanghai UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Zibo City First HospitalCollaborator
- Liaoning Hospital of Traditional Chinese MedicineCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Peking UniversityReponsible party - principal investigator
- Qingdao UniversityCollaborator
- Hubei University of Chinese MedicineCollaborator
- Haikou People's HospitalCollaborator
- Cangzhou Hospital of Integrated Traditional Chinese and Western MedicineCollaborator
- Wuhan UniversityCollaborator
- Tianshui Hospital of Traditional Chinese MedicineCollaborator
- Northwest UniversityCollaborator
- Shenzhen UniversityCollaborator
- Fujian Medical UniversityCollaborator
- The NO.4 People's Hospital of HengshuiCollaborator
- The First Hospital of Qiqihar CityCollaborator
- Guangzhou UniversityCollaborator
- The Airport Hospital of Shunyi DistrictCollaborator
- Shanxi College of Traditional Chinese MedicineCollaborator
- Zhengzhou UniversityCollaborator
- Shandong University of Traditional Chinese MedicineCollaborator
- People's Hospital of QuzhouCollaborator
- Liling Hospital of Traditional Chinese MedicineCollaborator
- Hunan University of Traditional Chinese MedicineCollaborator
- Guangzhou University of Chinese MedicineCollaborator
- Anshan Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.